← All trials
NCT05061901
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 6, 2021
- Primary completion
- Nov 6, 2021
- Completion date
- Nov 6, 2021
- First posted
- Sep 30, 2021
- Last posted
- Sep 30, 2021
- Enrollment
- 38
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pharmtechnology LLCLead sponsor
- CRO ClinPharmInvestOverall official - principal investigator
- CRO ClinPharmInvestCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.